Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Can NFκB2 be used as a biomarker for proteasome inhibitor response in MM?

Leon Bernal-Mizrachi, MD, of Emory University, Atlanta, GA, discusses a study aiming to characterize whether NFκB2 gene rearrangement can predict response to ixazomib in multiple myeloma. This Phase II trial tests ixazomib and dexamethasone vs. ixazomib, dexamethasone and lenalidomide, randomized with NFκB2 rearrangement (NCT02765854). This interview took place at the international myeloma workshop (IMW) 2019, in Boston, MA.